| [1] |
Chaker L, Cooper D S, Walsh J P, et al. Hyperthyroidism[J]. Lancet, 2024, 403(10428):768-780.
DOI
URL
|
| [2] |
Alam A, Sofi G, Quamri A. The perspective of unani medicine in understanding hyperthyroidism[J]. Altern Ther Health Med, 2023, 29(7):262-267.
|
| [3] |
Branstetter R M 4th, Islam R K, Toups C A, et al. Mechanisms and treatment options for hyperthyroid-induced osteoporosis:a narrative review[J]. Cureus, 2023, 15(11):e48798.
|
| [4] |
Jin J, Huang R, Chang Y, et al. Roles and mechanisms of optineurin in bone metabolism[J]. Biomed Pharmacother, 2024, 172:116258.
DOI
URL
|
| [5] |
Wu D, Li L, Wen Z, et al. Romosozumab in osteoporosis:yesterday,today and tomorrow[J]. J Transl Med, 2023, 21(1):668.
DOI
|
| [6] |
Park K R, Park J I, Lee S, et al. Chi3L1 is a therapeutic target in bone metabolism and a potential clinical marker in patients with osteoporosis[J]. Pharmacol Res, 2022, 184:106423.
DOI
URL
|
| [7] |
Lang A, Eastburn E A, Younesi M, et al. CYR61 delivery promotes angiogenesis during bone fracture repair[J]. NPJ Regen Med, 2025, 10(1):20.
DOI
PMID
|
| [8] |
卢秀波, 田文, 姜可伟, 等. 甲状腺功能亢进症外科治疗中国专家共识(2020版)[J]. 中国实用外科杂志, 2020, 40(11):1229-1233.
DOI
|
| [9] |
中华医学会骨质疏松和骨矿盐疾病分会, 章振林, 夏维波, 等. 原发性骨质疏松症诊疗指南(2022)[J]. 中华内分泌代谢杂志, 2023, 39(5):377-406.
|
| [10] |
宋云霄, 童巍, 张海晨, 等. 系统性炎症指标与老年骨质疏松症患者骨折发生的相关性[J]. 检验医学, 2022, 37(3):235-239.
DOI
|
| [11] |
Marini F, Giusti F, Palmini G, et al. Role of Wnt signaling and sclerostin in bone and as therapeutic targets in skeletal disorders[J]. Osteoporos Int, 2023, 34(2):213-238.
DOI
|
| [12] |
Sheng R, Cao M, Song M, et al. Muscle-bone crosstalk via endocrine signals and potential targets for osteosarcopenia-related fracture[J]. J Orthop Translat, 2023, 43:36-46.
DOI
URL
|
| [13] |
任艳霞, 李军, 李思源, 等. 绝经后2型糖尿病患者血清骨硬化蛋白表达与骨密度关系的研究[J]. 中国糖尿病杂志, 2021, 29(9):683-687.
|
| [14] |
Gao J, Xiang S, Wei X, et al. Icariin promotes the osteogenesis of bone marrow mesenchymal stem cells through regulating sclerostin and activating the Wnt/β-Catenin signaling pathway[J]. Biomed Res Int, 2021, 2021:6666836.
DOI
URL
|
| [15] |
Xu W, Chao R, Xie X, et al. IL13Rα2 as a crucial receptor for Chi3l1 in osteoclast differentiation and bone resorption through the MAPK/AKT pathway[J]. Cell Commun Signal, 2024, 22(1):81.
DOI
PMID
|
| [16] |
朱瑞, 马洪川, 陈华玲, 等. 2型糖尿病合并骨质疏松症患者血清Chi3L1 NEFAs与糖脂代谢及骨密度的相关性[J]. 河北医学, 2024, 30(3):448-453.
|
| [17] |
Hsu G C, Marini S, Negri S, et al. Endogenous CCN family member WISP1 inhibits trauma-induced heterotopic ossification[J]. JCI Insight, 2020, 5(13):e135432.
DOI
URL
|
| [18] |
杜娟, 卢晓丽, 张雪, 等. 弥漫性毒性甲状腺肿患者血清高半胱氨酸蛋白61及Fractalkine水平的表达及其临床意义[J]. 现代生物医学进展, 2022, 22(20):3987-3990.
|
| [19] |
Marinkovic M, Dai Q, Gonzalez A O, et al. Matrix-bound Cyr61/CCN1 is required to retain the properties of the bone marrow mesenchymal stem cell niche but is depleted with aging[J]. Matrix Biol, 2022, 111:108-132.
DOI
PMID
|
| [20] |
王方, 张欢, 付志远, 等. 血清CYR61、IL-17、Klotho蛋白对Graves眼病病情的评估价值[J]. 分子诊断与治疗杂志, 2024, 16(6):1165-1168.
|